C12.ai
About
About C12.ai
C12.ai develops physical-AI systems for automating laboratory experiments in drug discovery, chemistry and life sciences. Its robotic scientists operate instruments, move samples and execute protocols while software plans runs and captures structured experimental results.
Mobile manipulation allows the system to work across existing laboratory equipment instead of requiring every instrument to be rebuilt into one fixed line. Researchers define objectives and review outcomes while the platform handles repetitive execution and iteration. C12.ai combines laboratory robotics, experiment software and AI agents to increase the amount of physical data a research team can generate.
Funding
Investors
- Weihao Chuangxin - Participant - VC - 1 funding event - first seen 2026-03-12
- Yonghua Capital - Lead - VC - 1 funding event - first seen 2026-03-12
Team
- Jerry Chen - Founder & CEO - Leads C12.ai's physical-AI laboratory automation strategy, combining molecular AI with mobile robotic execution in pharmaceutical R&D labs.
Timeline
Events
- 2026-03-12 - Funding - C12.ai raises RMB 50M to advance Physical AI Scientists for drug discovery
C12.ai raised RMB 50M in a round led by Yonghua Capital, with participation from Weihao Chuangxin and individual investors. The funding follows deployment of Talos inside BeOne Medicines, where the system reportedly completed more than 3,000 operations over 50 days with zero errors. C12.ai combines molecular AI with robotic execution for drug-discovery and molecular-science workflows.
Source